Generic depo-subQ provera 104 Availability
See also: Generic Depo-Provera
DEPO-SUBQ PROVERA 104 (medroxyprogesterone acetate - injectable;subcutaneous)
Manufacturer: PHARMACIA AND UPJOHN
Approval date: December 17, 2004
Strength(s): 104MG/0.65ML [RLD]
Has a generic version of depo-subQ provera 104 been approved?
No. There is currently no therapeutically equivalent version of depo-subQ provera 104 available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of depo-subQ provera 104. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: About generic drugs.
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
Stabilized aqueous suspensions for parenteral use
Issued: December 17, 2002
Inventor(s): Giuseppe; Colombo & Alessandro; Martini & Lloyd E.; Fox
Assignee(s): Pharmacia & Upjohn SpA Pharmacia & Upjohn Company
A pharmaceutical aqueous suspension formulation for parenteral administration having substantially stabilized pH, comprising a biologically active compound and a pH controlling effective concentration of L-Methionine. Preferably, the biologically active compound is a steroidal compound, for instance exemestane, medroxyprogesterone acetate and estradiol cypionate or a combination of medroxyprogesterone acetate and estradiol cypionate.Patent expiration dates:
- May 15, 2020✓
- May 15, 2020
- Depo-subQ provera 104 injectable suspension (subcutaneous) Consumer Information (Wolters Kluwer)
- Depo-SubQ Provera 104 injection Consumer Information (Cerner Multum)
- Medroxyprogesterone Consumer Information (Drugs.com)
- Depo-Sub Q Provera Injectable Suspension (subcutaneous) Consumer Information (Wolters Kluwer)
- Medroxyprogesterone Consumer Information (Wolters Kluwer)
- Medroxyprogesterone injectable suspension Consumer Information (Wolters Kluwer)
- Medroxyprogesterone injectable suspension (subcutaneous) Consumer Information (Wolters Kluwer)
- Medroxyprogesterone Consumer Information (Cerner Multum)
- Medroxyprogesterone injection Consumer Information (Cerner Multum)
- Alti-Mpa Oral Advanced Consumer Information (Micromedex®)
- Medroxyprogesterone Advanced Consumer Information (Micromedex®)
- Medroxyprogesterone Intramuscular Advanced Consumer Information (Micromedex®)
- Medroxyprogesterone Acetate AHFS DI Monographs (ASHP)
|Drug Patent||A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.|
|Drug Exclusivity||Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.|
|RLD||A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.|